Filing Flows › Evofem Biosciences (EVFM) › Q1 2026
Evofem Biosciences (EVFM) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
Evofem Biosciences (EVFM) reported revenue of $899K for the first quarter 2026 (Q1 2026), +6% from a year earlier and -91% from the quarter before. Operating margin was -508.2%, net loss $5.5M (607.9% of revenue).
Evofem Biosciences, Q1 2026: revenue $899K (+6% year over year), operating margin -508.2%, net loss $5.5M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $899K | -91% | +6% |
| Operating profit | −$4.6M | -237% | -1497% |
| Net earnings | −$5.5M | -296% | -672% |
| Operating cash flow | $2.3M | 74× | +311% |
| Free cash flow | $2.3M | 82× | — |
What changed
Revenue was $899K in Q1 2026, up 6% year over year and down 91% from the previous quarter.
Operating costs exceeded revenue by $4.6M, an operating margin of -508.2%. Total costs grew 956% against revenue growth of 6%. The quarter ended with a net loss of $5.5M, after a profit of $2.8M the previous quarter.
Operating cash flow was $2.3M (up 311% year over year). Non-cash charges added back $79K of depreciation and amortization and $15K of share-based compensation. Working capital and other items added $7.7M. Capital expenditures of $2K left free cash flow of $2.3M.
Questions
What was Evofem Biosciences' revenue in the first quarter 2026?
Evofem Biosciences (EVFM) reported revenue of $899K for the first quarter 2026 (Q1 2026), +6% from a year earlier and -91% from the quarter before.
Was Evofem Biosciences profitable in the first quarter 2026?
Operating loss was $4.6M (-508.2% of revenue) and net loss $5.5M.
Source: Evofem Biosciences 10-Q on SEC EDGAR.